Breaking News Instant updates and real-time market news.

S

Sprint

$5.18

-0.23 (-4.25%)

, TMUS

T-Mobile

$56.98

-2.53 (-4.25%)

18:03
05/02/18
05/02
18:03
05/02/18
18:03

Sprint CEO doesn't expect to divest spectrum after T-Mobile deal, Bloomberg says

S

Sprint

$5.18

-0.23 (-4.25%)

TMUS

T-Mobile

$56.98

-2.53 (-4.25%)

S Sprint
$5.18

-0.23 (-4.25%)

05/02/18
OPCO
05/02/18
NO CHANGE
Target $90
OPCO
Outperform
Oppenheimer sees 80% chance of regulatory approval for T-Mobile/Sprint merger
Oppenheimer analyst Timothy Horan sees an 80% chance of regulatory approval for T-Mobile (TMUS)/Sprint (S) merger given pro-consumer/investment/jobs focus that scale drives, but with concessions. The analyst reiterates an Outperform rating and $90 price target on T-Mobile shares.
05/01/18
JEFF
05/01/18
UPGRADE
Target $5.5
JEFF
Hold
Sprint upgraded to Hold from Underperform at Jefferies
Jefferies analyst Scott Goldman upgraded Sprint (S) to Hold raised his price target for the shares to $5.50 from $4.50 following the company's merger agreement with T-Mobile (TMUS). The analyst sees the deal supporting the valuation into the regulatory review.
04/30/18
JPMS
04/30/18
NO CHANGE
JPMS
Neutral
JPMorgan sees near-term waves, long-term potential for Amdocs from Sprint deal
JPMorgan analyst Jackson Ader noted that Sprint (S) is a "much larger customer" of Amdocs (DOX) than T-Mobile is and he sees the balance of power in the combined company as a slight net negative for Amdocs. While he would expect short-term disruption to certain discretionary projects, he also notes that Amdocs has a relationship with both and "could easily come out the next 12-24 months in a better position," Ader tells investors. Though synergies is "never a good word for vendors," Ader thinks the move to a 5G network could create additional project and revenue opportunities, he added. He maintains a Neutral rating on Amdocs shares.
04/30/18
MSCO
04/30/18
NO CHANGE
MSCO
Morgan Stanley discusses T-Mobile deal implications for competitors, towers
After T-Mobile (TMUS) and Sprint (S) announced a merger agreement, Morgan Stanley analyst Simon Flannery said that while the $43B in estimated synergies is "impressive," the key question is how likely is it that the companies can gain regulatory approval. On competition, he thinks the deal may contribute to a more benign competitive environment in the near-term and that AT&T (T) and Verizon (VZ) could benefit from market consolidation, though he adds that the new T-Mobile would be a formidable competitor in new areas such as 5G and fixed broadband. Flannery added that the deal will be an overhang on tower and fiber providers, noting that part of their $4B in annual network synergies involves a reduction in tower counts from 110,000 to 85,000 over time. However, the analyst said he would expect much more gear to be deployed on each tower and small cells will still expand to 50,000 from 10,000. Tower operators include American Tower (AMT), Crown Castle (CCI) and SBA Communications (SBAC), which are all lower in pre-market trading.
TMUS T-Mobile
$56.98

-2.53 (-4.25%)

TODAY'S FREE FLY STORIES

IRWD

Ironwood

$11.96

0.32 (2.75%)

06:01
11/19/18
11/19
06:01
11/19/18
06:01
Recommendations
Ironwood analyst commentary  »

Ironwood price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:00
11/19/18
11/19
06:00
11/19/18
06:00
General news
FX Action: USD-JPY has retained a heavy tone »

FX Action: USD-JPY has…

YETI

Yeti

$16.99

0.1 (0.59%)

05:59
11/19/18
11/19
05:59
11/19/18
05:59
Initiation
Yeti initiated  »

Yeti initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RHHBY

Roche

$0.00

(0.00%)

05:57
11/19/18
11/19
05:57
11/19/18
05:57
Downgrade
Roche rating change  »

Roche downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 24

    Dec

NVS

Novartis

$87.74

0.52 (0.60%)

05:56
11/19/18
11/19
05:56
11/19/18
05:56
Upgrade
Novartis rating change  »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

TI

Telecom Italia

$6.02

0.12 (2.03%)

05:53
11/19/18
11/19
05:53
11/19/18
05:53
Hot Stocks
Telecom Italia appoints Luigi Gubitosi as CEO »

On Sunday, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STNE

StoneCo

$25.31

0.69 (2.80%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Initiation
StoneCo initiated  »

StoneCo initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Downgrade
AstraZeneca rating change  »

AstraZeneca downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

JPDYY

Japan Display

$0.00

(0.00%)

05:49
11/19/18
11/19
05:49
11/19/18
05:49
Downgrade
Japan Display rating change  »

Japan Display downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTRX

Retrophin

$25.17

0.44 (1.78%)

05:46
11/19/18
11/19
05:46
11/19/18
05:46
Initiation
Retrophin initiated  »

Retrophin initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

YETI

Yeti

$16.99

0.1 (0.59%)

05:43
11/19/18
11/19
05:43
11/19/18
05:43
Initiation
Yeti initiated  »

Yeti initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

EOLS

Evolus

$14.75

0.06 (0.41%)

05:40
11/19/18
11/19
05:40
11/19/18
05:40
Hot Stocks
Evolus announces conditional acceptance from FDA for Jeuveau brand name »

Evolus announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

MNK

Mallinckrodt

$30.85

-0.58 (-1.85%)

05:39
11/19/18
11/19
05:39
11/19/18
05:39
Upgrade
Mallinckrodt rating change  »

Mallinckrodt upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

CPAC

Cementos Pacasmayo

$9.98

(0.00%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Cementos Pacasmayo rating change  »

Cementos Pacasmayo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$11.65

0.27 (2.37%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Viking Therapeutics rating change  »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$23.04

-1.18 (-4.87%)

05:37
11/19/18
11/19
05:37
11/19/18
05:37
Earnings
Breaking Earnings news story on JD.com »

JD.com sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MDGL

Madrigal Pharmaceuticals

$129.47

-3.36 (-2.53%)

05:36
11/19/18
11/19
05:36
11/19/18
05:36
Downgrade
Madrigal Pharmaceuticals rating change  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

JD

JD.com

$23.04

-1.18 (-4.87%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Earnings
JD.com reports Q3 EPS 15c, consensus 10c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMH

American Homes 4 Rent

$19.83

-0.04 (-0.20%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Downgrade
American Homes 4 Rent rating change  »

American Homes 4 Rent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BB

BlackBerry

$8.97

0.12 (1.36%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Upgrade
BlackBerry rating change  »

BlackBerry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMAX

RE/MAX Holdings

$30.26

-0.23 (-0.75%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RE/MAX Holdings rating change  »

RE/MAX Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

RNG

RingCentral

$76.41

-0.54 (-0.70%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RingCentral rating change  »

RingCentral upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Upgrade
TD Ameritrade rating change  »

TD Ameritrade upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$46.97

-0.35 (-0.74%)

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Downgrade
Charles Schwab rating change  »

Charles Schwab downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

05:32
11/19/18
11/19
05:32
11/19/18
05:32
Hot Stocks
Nissan finds 'significant acts of misconduct' by Representative Director »

Nissan said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.